Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18)

被引：24

作者：

Kissling, Esther ^{[1
]}

Pozo, Francisco ^{[2
]}

Buda, Silke ^{[3
]}

Vilcu, Ana-Maria ^{[4
]}

Rizzo, Caterina ^{[5
,6
]}

Gherasim, Alin ^{[7
,8
]}

Horvath, Judit Krisztina ^{[9
]}

Brytting, Mia ^{[10
]}

Domegan, Lisa ^{[11
]}

Meijer, Adam ^{[12
]}

Paradowska-Stankiewicz, Iwona ^{[13
]}

Machado, Ausenda ^{[14
]}

Vucina, Vesna Visekruna ^{[15
]}

Lazar, Mihaela ^{[16
]}

Johansen, Kari ^{[17
]}

Durrwald, Ralf ^{[18
]}

van der Werf, Sylvie ^{[19
,20
]}

Bella, Antonino ^{[5
]}

Larrauri, Amparo ^{[7
,8
]}

Ferenczi, Annamaria ^{[9
]}

Zakikhany, Katherina ^{[10
]}

O'Donnell, Joan ^{[11
]}

Dijkstra, Frederika ^{[12
]}

Bogusz, Joanna ^{[13
]}

Guiomar, Raquel ^{[21
]}

Filipovic, Sanja Kurecic ^{[15
]}

Pitigoi, Daniela ^{[22
]}

Penttinen, Pasi ^{[17
]}

Valenciano, Marta ^{[1
]}

机构：

[1] Epiconcept, Epidemiol Dept, 47 Rue Charenton, F-75012 Paris, France

[2] Inst Hlth Carlos III, WHO Natl Influenza Ctr, Natl Ctr Microbiol, Natl Influenza Reference Lab, Madrid, Spain

[3] Robert Koch Inst, Dept Infect Dis Epidemiol, Resp Infect Unit, Seestr 10, D-13353 Berlin, Germany

[4] Sorbonne Univ, INSERM, Inst Pierre Louis Epidemiol & Sante Publ IPLESP U, F-75012 Paris, France

[5] Natl Inst Hlth, Dept Infect Dis, Rome, Italy

[6] Bambino Gesu Pediat Hosp, Rome, Italy

[7] Inst Hlth Carlos III, Natl Epidemiol Ctr, Madrid, Spain

[8] Inst Hlth Carlos III, CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain

[9] Off Chief Med Officer, Budapest, Hungary

[10] Publ Hlth Agcy Sweden, Stockholm, Sweden

[11] Hlth Serv Execut Hlth Protect Surveillance Ctr, 25-27 Middle Gardiner St, Dublin D01 A4A3 1, Ireland

[12] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands

[13] Natl Inst Hyg, Natl Inst Publ Hlth, Warsaw, Poland

[14] Inst Nacl Saude Dr Ricardo Jorge, Dept Epidemiol, Lisbon, Portugal

[15] Croatian Inst Publ Hlth, Zagreb, Croatia

[16] Cantacuzino Natl Med Mil Inst Res & Dev, Bucharest, Romania

[17] European Ctr Dis Prevent & Control ECDC, Gustav III S Blvd 40, S-16973 Solna, Sweden

[18] Natl Reference Ctr Influenza, Robert Koch Inst, Seestr 10, D-13353 Berlin, Germany

[19] Univ Paris Diderot SPC, Unit Genet Mol Virus ARN, Inst Pasteur, CNRS UMR3569, Paris, France

[20] Inst Pasteur, WHO Natl Influenza Ctr, CNR Virus Infect Resp, Paris, France

[21] Inst Nacl Saude Dr Ricardo Jorge, Dept Doencas Infeciosas, Lisbon, Portugal

[22] Carol Davila Univ Med & Pharm, Bucharest, Romania

来源：

VACCINE: X | 2019年 / 3卷

基金：

欧盟地平线“2020”;

关键词：

Influenza; Influenza vaccine; Vaccine effectiveness; Multicentre study; Case-control study; Europe; I-MOVE; ANTIBODY; BINDING; VIRUSES;

D O I：

10.1016/j.jvacx.2019.100042

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction: Influenza A(H3N2) viruses predominated in Europe in 2016-17. In 2017-18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017-18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity. Methods: We used the test-negative design in a multicentre primary care case-control study in 12 European countries to measure 2016-17 and 2017-18 influenza vaccine effectiveness (VE) against laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group. Results: During the 2017-18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI: 47-69). Among those aged 0-14, 15-64 and >= 65 years, VE against A(H1N1)pdm09 was 64% (95% CI: 37-79), 50% (95% CI: 28-66) and 66% (95% CI: 42-80), respectively. Overall VE against influenza A(H3N2) was 28% (95% CI: 17-38) in 2016-17 and 13% (95% CI: -15 to 34) in 2017-18. Among 0-14-year-olds VE against A(H3N2) was 28% (95%CI: -10 to 53) and 29% (95% CI: -87 to 73), among 15-64-year-olds 34% (95% CI: 18-46) and 33% (95% CI: -3 to 56) and among those aged >= 65 years 15% (95% CI: -10 to 34) and -9% (95% CI: -74 to 32) in 2016-17 and 2017-18, respectively. Conclusions: Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection against circulating strains, while VE against A(H3N2) was <35% in 2016-17 and 2017-18. The egg propagation derived antigenic mismatch of the vaccine seed virus with circulating strains may have contributed to this low effectiveness. A(H3N2) seed viruses for vaccines in subsequent seasons may be subject to the same adaptations; in years with lower than expected VE, recommendations of preventive measures other than vaccination should be given in a timely manner. (C) 2019 The Authors. Published by Elsevier Ltd.

引用

页数：10

共 37 条

[1] Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively [J].

Adlhoch, Cornelia ;

Snacken, Rene ;

Melidou, Angeliki ;

Ionescu, Silviu ;

Penttinen, Pasi .

EUROSURVEILLANCE, 2018, 23 (13) :7-12

[2]

[Anonymous], 2015, EUROPEAN UNION

[3]

[Anonymous], Stata Statistical Software

[4]

[Anonymous], 2016, REC COMP INFL VIR VA

[5] The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response [J].

Chen, Zhongying ;

Zhou, Helen ;

Jin, Hong .

VACCINE, 2010, 28 (24) :4079-4085

[6] EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS [J].

DAVENPORT, FM ;

HENNESSY, AV ;

FRANCIS, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1953, 98 (06) :641-656

[7]

ECDC, 2016, INFL VIR CHAR SUMM E

[8]

European Centre for Disease Prevention and Control, INFL VIR CHAR SUMM E

[9]

European Centre for Disease Prevention and Control (ECDC), 2010, EUR CTR DIS PREV CON

[10]

FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755

← 1 2 3 4 →